Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Am J Surg Pathol. 2016 Dec;40(12):1579–1590. doi: 10.1097/PAS.0000000000000744

Figure 2. KRAS mutation associations with overall survival (OS) and cumulative incidence of recurrence (CIR) in solid predominant tumors.

Figure 2

(A) In solid predominant tumors, 5-year OS of patients with KRAS-mutant tumors was significantly worse (n = 16; 5-year OS, 43%) than those with KRAS wild-type (n = 42; 77%; P = 0.008). (B) In solid predominant tumors, 5-year CIR of patients with KRAS-mutant tumors was significantly higher (5-year OS, 50%) than those with KRAS wild-type tumors (18%; P = 0.005).